FDA panel unanimously votes down Parkinson's drug

A panel of federal medical specialists has unanimously voted that a drug for Parkinson's disease from Teva Pharmaceuticals has not been shown to slow progress of the debilitating neurological disease.

Teva's Azilect is already approved to treat symptoms of Parkinson's, which causes tremors, and loss of balance.

Teva has asked the to expand approval so that it can be prescribed to slow the underlying disease. Currently no treatments are approved for that use.

But the FDA's panel of outside experts voted 17-0 against recommending approval for that use, saying the company's clinical study results were not convincing.

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

FDA panel unanimously backs Regeneron eye drug

Jun 17, 2011

(AP) -- A panel of federal health experts voted unanimously in favor of a new eye drug from Regeneron, bringing the company one step closer to competing against a blockbuster Roche drug that currently dominates the market.

Israeli generic drug giant Teva to buy Cephalon

May 02, 2011

Teva Pharmaceutical Industries, the world's largest generic drug maker, will buy US biopharma firm Cephalon in a $6.8 billion deal, the companies said in a joint statement Monday.

Novartis gains FDA approval for new MS drug

Sep 22, 2010

(AP) -- Federal health regulators have approved the first pill to treat the underlying causes of multiple sclerosis, a debilitating nervous system disorder that has traditionally been treated with injectable drugs.

Recommended for you

Xtoro approved for swimmer's ear

9 hours ago

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

10 hours ago

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

Judge halts Alzheimer's drug swap until July

Dec 16, 2014

A federal judge has ordered an Irish drug manufacturer to halt its plans to discontinue its widely used Alzheimer's medication, allegedly in an effort to drive patients to a newer patented drug.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.